Trial Profile
A biomarker study to evaluate circulating tumor cell count (CTC) and expression of pERK and pAKT in CTCs as biomarkers for sorafenib efficacy in patients with advanced hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 26 Dec 2015 New trial record